Long Term Results For Urologix(R) Cooled ThermoTherapy(TM) Presented At AUA

Main Category: Urology / Nephrology
Also Included In: Prostate / Prostate Cancer
Article Date: 26 May 2008 - 0:00 PDT

email to a friend   printer friendly   opinions  

Urologix®, Inc. (NASDAQ:ULGX) announced presentation of long-term clinical results from a multi-center trial with the Urologix Cooled ThermoCath® (CTC) Microwave Catheter for treatment of benign prostatic hyperplasia (BPH), also known as enlarged prostate, at the 2008 American Urological Association meeting in Orlando, Florida. CTC is a Cooled Thermotherapy catheter that is used exclusively with the Urologix CoolWave® or Targis® control units. The therapy is delivered in the comfortable setting of a physician's office with a treatment time of under 30 minutes. The results showed the efficacy of the CTC Microwave Catheter is durable for at least five years and the freedom from additional minimally invasive or surgical procedures is 90%. The data from the study showed clinically significant improvement from baseline of the three major BPH evaluation criteria: urinary flow rate, symptom improvement, and quality of life at the 5-year follow-up.

Alan Partin, MD, PhD, Chairman of the James Buchanan Brady Urological Institute at The Johns Hopkins Medical Institution, an investigator in the study, commented "Our long-term experience with the CTC Microwave Catheter demonstrated durability of response approaching conventional TURP and remarkable freedom from adverse events."

"Our support of this long term clinical trial is representative of our Company's commitment to science to better understand the benefits of the CTC Microwave Catheter for those affected by enlarged prostate disease. We believe these long term clinical results will aid physicians and patients in their decision making when weighing treatment options. This study demonstrates the effectiveness of the CTC Microwave Catheter in offering durable relief from symptoms of BPH for the majority of patients in a 30-minute treatment in a physician's office."

A complete review of the abstract along with a summary of the indications, contraindications, warnings and precautions of the treatment can be accessed at http://www.urologix.com.

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Urologix' products include the CoolWave®, Targis® and Prostatron® control units and the Cooled ThermoCath®, Targis® and Prostaprobe® catheter families. All of Urologix' products utilize Cooled ThermoTherapy™ a proprietary combination of microwave energy and cooling to protect healthy tissue and enhance patient comfort - and provide safe, effective, lasting relief of the symptoms of BPH.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "estimate" or "continue" or comparable terminology are intended to identify forward-looking statements. These statements are subject to certain risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company's Annual Report on Form 10-K for the year ended June 30, 2007 and other documents filed with the Securities and Exchange Commission.

http://www.urologix.com

• Additional
• References
• Citations